Florida Doc Agresti Banned from Prescribing After Fraud Conviction Hits
Published Date: 7/8/2025
Notice
Summary
Dr. Mark Agresti from Florida lost his DEA registration because he was convicted of health care fraud and excluded from federal health programs. He didn’t ask for a hearing, so the DEA canceled his registration by default. This means he can no longer legally prescribe controlled substances, effective immediately, impacting his medical practice and patients.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked; Prescribing Stopped
The DEA revoked Mark Agresti, M.D.'s Certificate of Registration No. BA2032441, effective August 6, 2025. Because his registration is revoked and future Florida registration applications are denied, he can no longer legally hold or renew a registration to prescribe controlled substances in Florida or lawfully prescribe controlled substances under that DEA number.
Mandatory Exclusion from Federal Health Programs
The record shows HHS/OIG mandatorily excluded Mark Agresti, M.D. from Medicare, Medicaid, and all Federal health care programs effective January 19, 2023, for a minimum period of 47 years. This exclusion follows his 2022 conviction for one count of conspiracy to commit health care fraud and wire fraud and 11 counts of health care fraud.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20552, Wellwise Pharmacy Inc.; Decision and Order
Wellwise Pharmacy in Texas had its DEA registration suspended and is facing revocation because it kept filling risky prescriptions for controlled drugs without checking warning signs. This affects the pharmacy’s ability to legally handle these medicines, protecting public health and safety. The decision took effect immediately in late 2025, stopping Wellwise from operating under its DEA license and signaling serious legal and financial trouble ahead.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
Previous / Next Documents
Previous: 2025-12609, Tanya Newlove, N.P.; Decision and Order
Tanya Newlove, a nurse practitioner from Illinois, lost her DEA registration because her state licenses expired and she didn’t ask for a hearing to defend herself. This means she can no longer handle controlled substances legally, effective immediately. If you’re a healthcare provider, this reminds you to keep your licenses current or risk losing important permissions.
Next: 2025-12611, Notice of Request To Release Airport Property; Waterloo Regional Airport (ALO), Waterloo, Iowa
The FAA wants to give up two pieces of land at Waterloo Regional Airport in Iowa and is asking the public what they think. This means the airport can use the land for other things, possibly bringing in new opportunities or money. If you care about the airport or local land use, now’s the time to speak up!